NCT02547428View on ClinicalTrials.gov

Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 3, 2015

Primary Completion Date

June 4, 2016

Study Completion Date

June 4, 2016

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

DRUG

CTN SR

CTN SR tablets, daily, Orally.

DRUG

Matching placebo

Matching-placebo tablets daily, orally.

Trial Locations (4)

32751

Maitland

34201

Bradenton

89128

Las Vegas

92660

Newport Beach

All Listed Sponsors

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT02547428 - Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) | Biotech Hunter | Biotech Hunter